Lexaria Bioscience (LEXX) Stock Statistics & Valuation Metrics

Lexaria Bioscience has a market cap or net worth of $25.11M. The enterprise value is .

Lexaria Bioscience has 17.56M shares outstanding. The number of shares has decreased by -2.65% in one year.

Lexaria Bioscience’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -73.79%.

The current PE Ratio of Lexaria Bioscience is -8.36. Lexaria Bioscience’s PEG ratio is 0.16.

In the last 12 months, Lexaria Bioscience had revenue of $525.92K and earned -$9.38M in profits. Earnings per share was -$0.61.

In the last 12 months, operating cash flow was -$7.38M and capital expenditures -$91.59K, giving a free cash flow of -$7.47M billion.

Lexaria Bioscience pays an annual dividend of , resulting in a dividend yield of

Lexaria Bioscience upcoming earnings date is Apr 14, 2023, TBA.

Lexaria Bioscience as a current ratio of 7.18, with Debt / Equity ratio of 0.02

In the past 12 months, Lexaria Bioscience has paid $0.00 in taxes.

Lexaria Bioscience EV to EBITDA ratio is -7.41, with an EV/FCF ratio of -8.48.

Lexaria Bioscience has $6.54M in cash and marketable securities with $123.72K in debt, giving a net cash position of -$6.42M billion.

Gross margin is 98.96%, with operating margin of -1239.16%, and net profit margin of -1248.25%.

The average price target for Lexaria Bioscience is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy